Cart summary

You have no items in your shopping cart.

Binimetinib

SKU: orb1305378

Description

Binimetinib (ARRY-162) is an orally bioavailable, selective MEK1/2 inhibitor (IC50=12 nM). It exhibits antitumor activity and is used in research for unresectable or BRAF V600E/K mutant metastatic melanoma. Its application extends to in vitro signaling studies and in vivo xenograft models investigating MAPK pathway inhibition.

Research Area

Cell Biology, Signal Transduction

Images & Validation

Key Properties

CAS Number606143-89-9
MW441.23
Purity99.00%
FormulaC17H15BrF2N4O3
SMILESCn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO
TargetMEK,Autophagy
SolubilityEthanol:< 1 mg/mL (insoluble or slightly soluble);DMSO:50 mg/mL (113.32 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.53 mM);H2O:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

Target IC50
MEK:12 nM
In Vivo
ARRY-438162 is an ATP non-competitive inhibitor for MEK1/2, capable of inhibiting intracellular pERK with an IC50 of 11 nM. When used in combination, MEK162 (1 μM) and MK-2206 (2 μM) can fully reverse the resistance of MCF7 cells expressing RSK. ARRY-438162 at 2 μM exhibits minimal impact on osteoblast differentiation. At a concentration of 10 μM, ARRY-438162 inhibits osteoclast resorption in vitro with an IC50 of 625 nM. Additionally, ARRY-438162 at 625 nM suppresses osteoclast differentiation in vitro with an IC50 of 39 nM.
In Vitro
In models of collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) in rats, ARRY-438162 demonstrated significant anti-inflammatory effects. At doses of 1/3 mg/kg administered twice daily orally (p.o.), ARRY-438162 reduced ankle diameter swelling by 27%/50% in the CIA model, outperforming ibuprofen's 46% reduction. Higher doses of 3/10 mg/kg showed 11%/34% inhibition of ankle swelling in the AIA model. Moreover, in immunodeficient mice injected with MCF7-RSK4 cells, the combination of ARRY-438162 (6 mg/kg, twice daily) with BEZ235 significantly diminished tumor growth. In the AIA rat model, ARRY-438162 (10 mg/kg) completely suppressed serum IL-6 concentrations in a dose-dependent manner compared to controls. Similarly, in both CIA and AIA rat models, administration of ARRY-438162 (10 mg/kg, twice daily p.o.) dose-dependently ameliorated disease severity. The same dosing regimen significantly mitigated lesions (inflammation, cartilage damage, angiogenesis, and bone resorption) in the CIA model, with 1/3 mg/kg doses inhibiting these effects by 32% and 60%, respectively. Furthermore, in the AIA rat model, ARRY-438162 at 10/30 mg/kg doses significantly and dose-dependently reduced ankle swelling compared to control groups.
Cell Research
MEK162 is dissolved in DMSO and stored, and then diluted with appropriate medium before use. MCF7 cells infected as indicated are seeded in 12-well plates (2×104). After 24 hours, cells are treated with BEZ235 (100 or 200 nM), BKM120 (0.75 or 1 μM), GDC-0941 (1 μM), or MK2206 (2 μM) alone or in combination with MEK162 (1 μM), BI-D1870 (10 μM), or AZD6244 (1 μM), as indicated in text. Cell numbers are quantified by fixing cells with 4% glutaraldehyde or methanol, washing the cells twice in Water, and staining the cells with 0.1% crystal violet. The dye is subsequently extracted with 10% acetic acid, and its absorbance is determined (570 nm). Growth curves are performed in triplicate. Viability assays with CellTiter-Glo are performed by plating 2,000 cells in 96-well plates, adding the drug at 24 hours, and assaying 4 to 5 days after drug addition. Cell-cycle and hypodiploid apoptotic cells are quantified by flow cytometry. Briefly, cells are washed with PBS, fixed in cold 70% ethanol, and then stained with propidium iodide while being treated with RNase. Quantitative analysis of sub-G1 cells is carried out in a FACScalibur cytometer using Cell Quest software.

Storage & Handling

StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Inhibitor, inhibit, Mitogen-activated protein kinase kinase, MAP2K, MAPKK, MEK162, MEK-162, MEK 162, MEK, Autophagy, ARRY 162, ARRY438162, ARRY-438162, ARRY 438162, ARRY162, ARRY-162, Binimetinib

Similar Products

  • Binimetinib Isomer Impurity-13C-d3 [orb2281006]

    445.24

    13C C16H12BrF2N4O3D3

    5 mg, 1 mg, 10 mg
  • Binimetinib-13C-d3 [orb2281007]

    445.24

    C17H15BrF2N4O3

    5 mg, 1 mg, 10 mg
  • Binimetinib [orb1224490]

    >98% (HPLC)

    606143-89-9

    441.23

    C17H15BrF2N4O3

    1 g, 500 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Key Properties

No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Binimetinib (orb1305378)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
$ 80.00
10 mg
$ 100.00
1 ml x 10 mM (in DMSO)
$ 110.00
25 mg
$ 110.00
50 mg
$ 120.00
100 mg
$ 140.00
200 mg
$ 200.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry